Management of patients with follicular lymphoma treated first line with obinutuzumab

In Associate Professor Chan Cheah’s latest co-authored publication, he looks at patients with Follicular Lymphoma who are treated with Obinutuzumab as their first treatment option:

“Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade ≥3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.” – Abstract above from website